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ABSTRACT
Background: Patients with chronic intestinal failure (CIF) often
develop cholestatic liver injury, which may lead to liver failure and
need for organ transplantation.
Objectives: The aim of this study was to investigate whether
citrulline (CIT) and the enterokine fibroblast growth factor 19
(FGF19) are associated with chronic cholestasis and survival in adult
CIF patients, and to develop a risk score to predict their survival.
Methods: We studied 135 adult CIF patients on intravenous
supplementation (>3 mo). Associations of plasma CIT and FGF19
with chronic cholestasis and survival were estimated by logistic and
Cox regression models. A predictive risk score was developed and
validated internally.
Results: Patients with chronic cholestasis (17%) had a reduced 5-
y survival rate compared with patients without chronic cholestasis
(38% and 62%, respectively). In multivariable analysis, low FGF19,
low CIT, and female sex were associated with chronic cholestasis.
Patients with low rather than high CIT or FGF19 also had reduced 5-
y survival rates (29% compared with 69%; 54% compared with 66%,
respectively). Risk factors identified in multivariable analysis of
survival were low FGF19 (HR: 3.4), low CIT (HR: 3.3), and number
of intravenous infusions per week (HR: 1.4). These 3 predictors
were incorporated in a risk model of survival termed Model for
End-Stage Intestinal Failure (MESIF) (C-statistic 0.78). The 5-y
survival rates for patients with MESIF scores of 0 to <20 (n = 47),
20–40 (n = 75), and >40 (n = 13) were 80%, 58%, and 14%,
respectively.
Conclusions: CIT and FGF19 predict chronic cholestasis and
survival in this cohort of adult CIF patients, and the derived MESIF
score is associated with their survival. Pending external validation,
the MESIF score may help to identify patients for closer clinical
monitoring or earlier referral to intestinal transplantation centers.
Am J Clin Nutr 2019;109:1620–1629.
Keywords: intestinal failure, chronic cholestasis, FGF19, citrulline,
home parenteral nutrition
Introduction
Patients with chronic intestinal failure (CIF) require long-term
intravenous supplementation (IVS) to maintain adequate protein,
energy, fluid, and electrolyte balance; availability of essential
micronutrients andminerals; and to achieve longer survival (1, 2).
CIF is considered an orphan disease with a prevalence in adults of
12 permillion habitants in the Netherlands according to the Dutch
Registry of Intestinal Failure and Intestinal Transplantation,
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launched in February 2013 (3). Care for these patients is complex
and requires a multidisciplinary approach (3, 4).
Between 24% and 65% of CIF patients develop liver injury
(e.g., steatosis, cholestasis, or fibrosis), collectively known
as intestinal failure–associated liver disease (IFALD) (5–9).
Ultimately, IFALD may progress to liver failure, which is
accompanied by higher rates of referral for intestinal or
multivisceral transplantation (ITx) and home parenteral nutrition
(HPN)-related mortality (10). Currently, no scoring instruments
are available to predict the risk of development of cholestatic liver
injury and mortality in adult (or pediatric) CIF patients.
Fibroblast growth factor 19 (FGF19) is an ileum-derived
enterokine that is induced by enteral feeding. FGF19 targets the
liver to regulate key metabolic processes including energy and
lipid metabolism, and maintains hepatic bile salt homeostasis
by controlling bile salt synthesis (11, 12). Several studies
demonstrated dysregulated bile salt synthesis in experimental
and clinical (pediatric) IFALD, indicating an etiologic role of
excessive concentrations of hepatic bile salts (13–15). In animal
studies, FGF19 ameliorated cholestatic liver injury by restoring
bile salt homeostasis or repression of proinflammatory cascades
(16–18). Moreover, low concentrations of FGF19 in pediatric
patients with short bowel (SB) syndrome were related to hepatic
fibrosis and portal inflammation (19).
Citrulline (CIT), a nonproteinaceous amino acid produced in
the enterocyte through the glutamine–ornithine pathway, is a
powerful marker of the absorptive function of the remnant small
bowel (20). Because massive loss of small intestinal tissue is
associated with cholestatic liver injury in parenteral nutrition–
dependent patients, it could be anticipated that low CIT also
predicts development of cholestasis in CIF patients (21).
Taken together, we hypothesized that low FGF19, especially
with absent or limited enteral intake or after ileal resection, and
inadequate small intestinal absorptive capacity, reflected by low
CIT, could accurately predict the risk of cholestatic liver injury
and mortality. The aims of this study were 1) to estimate the
predictive performance of the intestinal factors CIT and FGF19
for chronic cholestasis and to assess if these factors are associated
with survival in adult CIF patients, and 2) to develop a prognostic
scoring system to predict their survival.
Methods
Study population
This study was a retrospective analysis on a prospectively
collected cohort of 193 consecutive adult patients who visited
the outpatient clinic of the Department of Gastroenterology of
Radboud University Medical Center (Nijmegen, Netherlands)—
a tertiary referral center for Intestinal Failure (IF) support—
between 2007 and 2017. Patients who had received IVS for ≥
3 mo at the time of blood collection, and for whom clinical data
and a blood sample were available, were considered for inclusion.
Before database building, we excluded patients with obstructive
cholestasis caused by biliary malignancies or autoimmune
diseases (e.g. primary sclerosing cholangitis). All patient plasma
samples were obtained as part of routine clinical care during
clinic visits and stored surplus plasma samples were analyzed in
this study. Blood samples were collected between January, 2007
and February, 2017. Fifty-eight patients were excluded from this
study. See Supplemental Figure 1 for a detailed overview of the
excluded patients. This studywas approved by theMedical Ethics
Committee of Radboud University (no. 2016-2714).
Data collection and definitions
Data were collected from patient medical files. Castor
Electronic Data Capture, a web-based electronic platform, was
used for data management. The following items were collected:
date of birth, sex, body weight, length, BMI, underlying disease,
reason for IVS, age at start of IVS, age at day of blood sample,
duration of IVS (defined as the difference in time [months]
between the start date of IVS and day of blood collection),
infused volume per day, frequency of intravenous infusions per
week (number between 1 and 7), calories provided by IVS,
infusion of intravenous lipids, cholecystectomy, bowel anatomy
and oral intake, liver tests, C-reactive protein, Fibroscan value (if
available), death and cause of death (if applicable), and hepatitis
B and C serologic test results. Chronic cholestasis and survival
were the main outcome parameters. Chronic cholestasis was
assessed according to Cavicchi et al. (5) as persistent elevation
(> 1.5 times the upper limit of the normal range) of ≥ 2
cholestatic markers (alkaline phosphatase [ALP], γ -glutamyl
transferase [GGT], and total bilirubin) for ≥ 6 mo. Chronic
cholestasis was assessed at the day of blood collection. In case
multiple blood samples since the start of IVS were available
for a given patient, the most recent blood sample (end date:
22 February, 2017) was used for CIT/FGF19 measurements.
Total intravenous energy intake (in kilocalories) and intravenous
lipids infused (in grams) per day, adjusted for body weight and
number of infusions per week, were calculated according to the
manufacturer’s formulations. The small bowel anatomy of all
patients was assessed, in particular the presence or absence of
the terminal ileum. For data analysis small bowel anatomy was
dichotomized, i.e., 1) the terminal ileum was (partially) in situ,
or 2) the complete ileum was resected or the terminal ileum was
not preserved. Remnant small bowel length was categorized into
4 groups: 1) > 200 cm (including patients with no resection), 2)
> 100 to≤ 200 cm, 3)≥ 50 to≤ 100 cm, and 4)<50 cm. A cutoff
of 107 pg/mL for plasma FGF19 was used for all data analyses
(based on the median fasted FGF19 concentrations in 18 healthy
males, see below) and a cutoff concentration of 20 μmol/L for
plasma CIT was used. The latter was previously shown to be the
lower limit for sufficient absorptive function (20).
Blood samples and analytical procedures
Bloodwas collected in EDTA-coated tubes and derived plasma
was stored at −20◦C (at Radboud University Medical Center)
until further analysis. Plasma FGF19 was assayed by sandwich
ELISA as described previously (22). FGF19 cutoffs were derived
from analysis of plasma samples (n= 18male healthy volunteers,
median [IQR] age: 23 [19, 27] y) obtained after an overnight
fast. These samples were collected between 2014 and 2018 in
the framework of other studies (MR Soeters, unpublished data).
Plasma CIT was measured by HPLC (23). Plasma 7α-hydroxy-
4-cholesten-3-one (C4, plasma marker of bile salt synthesis)
was assessed by liquid chromatography-mass spectrometry as
described previously (22). Plasma total bile salts (TBS) were
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measured by an enzymatic cycling method according to the
manufacturer’s protocol (Diazyme).
Statistical analysis
Data are expressed as frequency (percentage), median [IQR],
or mean ± SD as appropriate. For contingency analysis, the
chi-square test of independence was used. Differences between
2 groups on continuous variables were tested using the Mann–
Whitney U test or Student’s t test, depending on the distribution
of the data. The Kruskal–Wallis test with Dunn’s multiple-
comparison post hoc test was used when comparing ≥ 3 groups.
Correlations were evaluated by Spearman rank correlation
coefficients (ρ). Univariable and multivariable binary logistic
regression analysis was performed to identify predictors of
chronic cholestasis. The −2 log-likelihood was used to compare
and choose the best fit of the regression models. Survival curves
were calculated using the Kaplan–Meier method. Differences
between groups were assessed using the log-rank test. In survival
analyses, time zero was set as the day of blood collection and
subjects were censored by death, end of the follow-up period, or
loss to follow-up. The censoring date used for survival analyses
was 22 November, 2017. Univariable and multivariable Cox
proportional hazard regression analysis was used to identify
independent predictors of survival. Selection of covariates for
multivariable logistic regression and Cox proportional hazard
regression analysis was based on the following criteria: P values
<0.20 in the univariable analysis or based on the research
question. For covariate selection a force entry strategy was used
to optimally select relevant covariates. A risk score predicting
survival was developed and themodel performancewas evaluated
by assessing the concordance (C) statistic. Internal validation
using a bootstrap method was used to correct the C-statistic
for optimism. A C-statistic > 0.7 denotes a clinically useful
test and values between 0.8 and 0.9 are considered to have
excellent predictive value. P values <0.05 were considered
statistically significant. To study longitudinal differences of
FGF19 or CIT in cases where multiple samples were available,
the difference between the first and most recent measurements
of FGF19 (FGF19) or CIT (CIT) was used and analyzed
using linear regression with the time difference (in months)
between the 2 measurements as the covariate. Statistical analyses
were performed using IBM SPSS Statistics version 24 (IBM
Corporation) or R statistical software and associated packages (R
Foundation for Statistical Computing).
Results
Patients’ characteristics
Data from 135 patients (mean age at start of IVS: 50.3 y,
74% females) were included in this study. Details of the total
cohort of patients stratified for chronic cholestasis are displayed
in Table 1. The duration of IVS therapy (time between the
start of IVS and day of blood collection for the FGF19/CIT
assay) was 46 [14, 83] mo. Nineteen patients received only
intravenous fluids, whereas 116 patients were supplemented with
HPN (see Supplemental Table 1 for a detailed overview of
the type of IVS). Ten patients had a history of gastrointestinal
malignancy, but none of these patients had residual cancer or
signs of recurrence of cancer during IVS. Inherent to stratification
criteria, patients with chronic cholestasis had higher GGT, ALP,
and total bilirubin concentrations. In addition, transaminases
were higher in this group. None of the patients had active hepatitis
B or C infection.
Plasma CIT, TBS, FGF19, and C4 concentrations were
related to the mechanism of IF
First, we studied plasma concentrations of CIT, TBS, FGF19,
and C4 across the different causes of IF (Table 2). CIT
and TBS concentrations were comparable in all groups. In
contrast, FGF19 concentrations were significantly lower in SB
patients than in intestinal dysmotility patients (P < 0.0001),
mechanically obstructed patients (P = 0.005), and healthy
controls at baseline (P < 0.0001). Low FGF19 concentrations
in SB patients were accompanied by high C4 concentrations,
indicating dysregulated bile salt homeostasis in this group.
C4 concentrations in SB patients were notably higher than in
patients with intestinal dysmotility (P < 0.0001) and patients
with mechanical obstruction (P = 0.016). FGF19 and C4
were negatively correlated across all patients (ρ = −0.77,
P < 0.0001) and in all cause-of-IF groups (ρ range: −0.41 to
−0.96, P < 0.001), in line with FGF19 suppressing bile salt
synthesis. CIT and FGF19 were not correlated across all patients
(ρ = −0.04, P = 0.64), or in any of the cause-of-IF groups. As
expected, both CIT and FGF19 concentrations were associated
with small bowel length (ρ = −0.32, P = 0.0004; ρ = −0.55,
P< 0.0001, respectively) (Supplemental Figure 2A).Moreover,
FGF19 concentrations were significantly lower in CIF patients
who underwent terminal ileum resection than in CIF patients
with preserved terminal ileum (P < 0.0001). Conversely, C4
concentrations were higher in CIF patients without a terminal
ileum than in patients with preserved terminal ileum (P< 0.0001)
(Supplemental Figure 2B). TBS and CIT concentrations were
comparable in patients with resected or preserved terminal
ileum.
Low circulating concentrations of CIT and FGF19 predicted
chronic cholestasis in adult CIF patients
Next, we investigated the association between selected
variables and chronic cholestasis. As shown in Table 1, 23
patients (17.1%) had chronic cholestasis in this cohort. The 5-y
survival rate of patients with chronic cholestasis was significantly
lower than that of patients without chronic cholestasis (38%
compared with 62%, P= 0.009) (Figure 1). Univariable analysis
revealed that terminal ileum resection (P = 0.021), small bowel
length (P = 0.002), prior cholecystectomy (P = 0.015), low
FGF19 (P = 0.038), and low CIT (P = 0.001) concentrations
were significant predictors of chronic cholestasis (Table 3).
Multivariable analysis showed that low CIT (P = 0.002) and
low FGF19 (P = 0.049), adjusted for sex (P = 0.021),
were significant independent predictors of chronic cholestasis
(Table 3).
Low CIT and low FGF19 concentrations were associated
with reduced survival of adult CIF patients
Because low concentrations of CIT and FGF19 were as-
sociated with chronic cholestasis, and patients with chronic
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TABLE 1 Patient characteristics1
Item Total cohort No chronic cholestasis Chronic cholestasis P value
Patients 135 (100) 112 (83) 23 (17)
Female 100 (74) 79 (71) 21 (91) 0.038
Age at start of IVS, y 50.3 ± 15.2 49.7 ± 14.5 53.1 ± 17.9 0.353
Age at day of blood sample, y 55.9 ± 14.5 55.3 ± 14.0 58.8 ± 16.7 0.329
BMI, kg/m2 22.2 ± 3.9 22.1 ± 3.6 22.4 ± 5.0 0.740
Duration of IVS,2 mo 46.0 [14.0, 83.0] 45.5 [14.0, 88.0] 52.0 [14.0, 81.0] 0.902
Frequency of HPN infusion (n = 116) 5.0 [3.5, 7.0] 5.5 [3.5, 7.0] 5 [3.5, 7.0] 0.429
IVS volume, mL/d (n = 115) 1408 ± 542 1385 ± 549 1505 ± 516 0.353
Energy intake, kcal · kg−1 · d−1 (n = 121) 22.5 ± 11.6 22.3 ± 12.0 23.5 ± 9.9 0.664
i.v. lipids, g · kg−1 · d−1 (n = 115) 0.72 ± 0.48 0.74 ± 0.48 0.61 ± 0.47 0.245
IVS type
i.v. fluids only 19 (14) 18 (16) 1 (4) 0.141
Reason for HPN
Short bowel 58 (43) 43 (39) 15 (65) 0.018
Enterocutaneous fistula 7 (5) 5 (5) 2 (9) 0.341
Intestinal dysmotility 49 (36) 46 (41) 3 (13) 0.011
Mechanical obstruction 3 (2) 2 (2) 1 (4) 0.432
Extensive small bowel mucosal disease 7 (5) 5 (5) 2 (9) 0.341
Other 11 (8) 11 (10) 0 (0) 0.117
Underlying etiology
Inflammatory bowel disease 28 (21) 24 (21) 4 (17) 0.664
Bowel obstruction 8 (6) 7 (6) 1 (4) 0.725
Mesenteric thrombosis 16 (12) 12 (11) 4 (17) 0.476
Bowel ischemia, nonthrombotic 8 (6) 3 (3) 5 (22) 0.004
Complicated abdominal surgery 2 (2) 1 (1) 1 (4) 0.313
Congenital GI abnormality 1 (1) 1 (1) 0 (0) 1.000
GI malignancy 10 (7) 7 (6) 3 (14) 0.374
CIP 43 (32) 40 (36) 3 (13) 0.034
Volvulus 5 (4) 4 (4) 1 (4) 1.000
Radiation enteritis 6 (4) 6 (5) 0 (0) 0.589
Other 8 (6) 7 (6) 1 (4) 1.000
Surgical anatomy
Terminal ileum resection, yes 69 (51) 52 (47) 17 (74) 0.014
Small bowel length
≥ 200 cm 70 (52) 64 (57) 6 (26) 0.007
≥ 100 – <200 cm 19 (14) 14 (13) 5 (22) 0.305
≥ 50 – <100 cm 17 (13) 11 (10) 6 (26) 0.043
<50 cm 13 (10) 8 (7) 5 (22) 0.046
Unknown 16 (12) 15 (13) 1 (4) 0.306
Colon not in continuity with small bowel 39 (29) 31 (28) 8 (35) 0.494
Cholecystectomy 36 (27) 25 (22) 11 (48) 0.012
Liver tests3
ALAT, IU/L 26 [19, 43] 24 [18, 36] 53 [28, 116] 0.007
ASAT, IU/L 27 [22, 39] 25 [21, 33] 43 [30, 53] 0.023
GGT, IU/L 38 [20, 101] 29 [18, 57] 204 [124, 388] 0.001
ALP, IU/L 110 [88, 156] 103 [81, 131] 274 [189, 365] <0.0001
Total bilirubin, μmol/L 7 [5, 11] 6 [4, 10] 14 [9, 22] 0.007
1Values are mean ± SD, median [IQR], or frequency (n, %). The chi-square test of independence, Mann–Whitney U test, or Student’s t test (depending
on the distribution of the data) was used to compare groups. ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, aspartate aminotransferase;
CIP, chronic intestinal pseudo-obstruction; GGT, γ -glutamyl transferase; GI, gastrointestinal; HPN, home parenteral nutrition; i.v., intravenous; IVS,
intravenous supplementation.
2Duration of IVS is the time difference between the start of IVS and day of blood collection.
3Measured at the day of blood collection.
cholestasis had reduced 5-y survival, we further investigated the
association between low CIT or low FGF19 and survival. The
survival rates after the start of IVS were 94%, 85%, and 71%
at 2, 5, and 10 y, respectively. Twenty-nine patients (22%) died
during follow-up, because of their underlying disease (n = 8),
central venous catheter–related sepsis (n = 2), and other causes
(n = 13). The cause of death was unknown in 6 patients (owing
to loss to follow-up) (Supplemental Table 2). Patients with
low CIT had a reduced 5-y survival compared with patients
with CIT concentrations > 20 μM (29% compared with 69%,
P < 0.0001, Figure 2A). Likewise, patients with low FGF19
tended to have a lower 5-y survival than patients with high
FGF19 concentrations (54% compared with 66%, P = 0.060,
Figure 2B).
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TABLE 2 CIT, TBS, FGF19, and C4 concentrations related to the mechanism of intestinal failure1
Item CIT (μmol/L)
Adjusted
P value TBS (μmol/L)
Adjusted
P value FGF19 (pg/mL)
Adjusted
P value C4 (ng/mL)
Adjusted
P value
Correlation
FGF19 vs. C4
(ρ, P value)
Mechanism of intestinal failure
SB (n = 58) 34 [23, 49] Ref 4 [3, 9] Ref 16 [9, 44] Ref 148 [78, 260] Ref −0.59, <0.0001
Intestinal fistula (n = 7) 28 [20, 36] NS 7 [5, 10] NS 57 [41, 432] NS 28 [3, 211] NS −0.96, <0.0001
Intestinal dysmotility (n = 49) 39 [32, 51] NS 4 [3, 11] NS 120 [50, 366] <0.0001 15 [7, 43] <0.0001 −0.41, <0.0001
Mechanical obstruction (n = 3) 41 [33, 44] NS 9 [1, 13] NS 287 [129, 691] 0.005 7 [3, 34] 0.016 −0.50, <0.0001
ESMD (n = 7) 26 [16, 34] NS 7 [6, 20] NS 62 [16, 280] NS 15 [8, 147] NS −0.79, <0.0001
Healthy controls
Baseline (fasted) (n = 18) N/A N/A N/A N/A 107 [87, 134] <0.0001 N/A N/A N/A
1Values are median [IQR]. SB is used as a reference category for the adjusted P values. The Kruskal–Wallis test with Dunn’s multiple-comparison post hoc test was used to compare between groups with
SB as the reference group. Correlations were evaluated by Spearman rank correlation coefficients (ρ). CIT, citrulline; ESMD, extensive small bowel mucosal disease; FGF, fibroblast growth factor; N/A, not
available; NS, nonsignificant; Ref, reference group; SB, short bowel; TBS, total bile salts.
Results from univariable and multivariable Cox proportional
hazard regression analyses are depicted in Table 4. Univariable
Cox regressions identified frequency of intravenous infusions per
week (HR: 1.32, P = 0.027) and low CIT (HR: 3.64, P < 0.001)
as significant predictors of survival. Low FGF19 tended to be a
predictor of survival (HR: 2.81, P = 0.056) (Table 4).
In the multivariable Cox regression analysis, low FGF19
became a significant predictor of outcome (HR: 3.35, P= 0.032)
when adjusting for low CIT (HR: 3.34, P= 0.004) and frequency
of intravenous infusions per week (HR: 1.39, P = 0.011). All
variables had a variance inflation factor of 1.0, indicating lack of
multicollinearity between variables.
FIGURE 1 Kaplan–Meier curves for adult intestinal failure patients with
and without chronic cholestasis during a 5-y observation period. Patients
with chronic cholestasis had a significantly lower survival rate than patients
without chronic cholestasis (log-rank test, P = 0.009).
Development of a scoring system to predict survival in adult
CIF patients
Because CIT, FGF19, and frequency of intravenous infusions
per week were associated with survival and are simple objective
parameters, we developed a scoring system, termed Model for
End-Stage Intestinal Failure (MESIF), to predict survival in adult
CIF patients. Such a model could be useful to identify potential
ITx candidates at an early stage or to stratify patients who need
closer clinical monitoring.
The formula for calculating the MESIF score was derived
from multivariable Cox proportional hazard regression analysis.
The estimates of the regression coefficients were incorporated
in a formula and multiplied by 10 to simplify the scoring:
MESIF score = 12.05·CIT + 12.09·FGF19 + 3.29·Frequency
of intravenous infusions per week (i.e., the number of days per
week that IVS is given). CIT is scored as 0 (> 20 μmol/L) or
1 (≤ 20 μmol/L), FGF19 is scored as 0 (> 107 pg/mL) or 1 (≤
107 pg/mL), and frequency of intravenous infusions per week is
a score between 1 and 7. Accordingly, MESIF scores can range
between 3 and 47.
We evaluated the predictive performance of the MESIF score
by computing the C-statistic, a value that indicates discriminative
performance. The C-statistic was 0.78 (95% CI: 0.65, 0.91)
for the initial model. Because regression coefficients from
multivariable regressions are prone to be overestimated, the final
model was validated internally using bootstrap resampling, and
resulted in an optimism-corrected C-statistic of 0.76 indicating
good discriminative performance. Using the MESIF score, we
stratified patients according to their scores into 3 arbitrary risk
groups. The 5-y survival rates for groups with scores of 3 to ≤
20 (low-risk group), 20–40 (intermediate-risk group), or > 40
points (high-risk group) were 80%, 58%, and 14%, respectively
(P < 0.0001) (Figure 3).
The time span between initiation of IVS and blood sampling
varied for the FGF19/CIT assay, ranging from 3 to 484 mo.
For 80 of the 135 patients, ≥ 2 longitudinal plasma samples
covering this interval were available. Linear regression analyses,
with FGF19 or CIT (i.e., the difference between the first and
most recent plasma values) as the dependent factor and time
(ranging between 3 to 484 mo) as the covariate, revealed that
time did not have a significant influence on longitudinal FGF19
(n = 80; P = 0.693) or CIT (n = 71; P = 0.624) plasma values.
Thus, FGF19/CIT values remain quite stable over a longer period
of IVS dependency.
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Discussion
In this (single-center, Dutch) CIF patient cohort study, wewere
able to investigate the relation of clinical and gut-derived factors
with chronic cholestatic liver injury and survival. The main
finding of this study is that low CIT and FGF19, both gut-derived
factors, are strongly associated with chronic cholestasis and poor
survival in adult patients with CIF. Furthermore, we developed a
simple risk score, the MESIF score, to predict survival in adult
CIF patients. Of note, a tool to guide clinical practice is currently
not available.
Chronic cholestatic liver injury is strongly associated with
severe parenteral nutrition–related liver disease andmay progress
to liver failure (5). In the case of end-stage liver disease, intestine
or combined liver–intestine transplantation is the only viable
treatment option (10). Previously recognized risk factors for
chronic cholestatic liver injury were small bowel length (<50
cm), lipid emulsions containing solely soybean oil, and high-dose
parenteral lipids ≥ 1 g · kg−1 · d−1 (5). Since then, multiple
strategies have been implemented in clinical care guidelines
to reduce the risk of IFALD, including sepsis management,
preserving small bowel length, maintaining small bowel–colon
continuity, promoting oral/enteral intake, limiting lipid supple-
mentation to <1 g · kg−1 · d−1, and minimizing soybean oil
content (1). Of note, it has been shown that phytosterols, major
constituents of soybean oil, promote cholestatic liver disease,
highlighting the need to minimize use of soybean oil–based lipid
emulsions to prevent cholestatic liver injury (24, 25). Although
liver failure due to IFALD remains the main indication for
intestine or combined liver–intestine transplantation, more recent
studies showed declines in the prevalence of chronic cholestatic
liver injury (20–30%) relative to the 50% prevalence reported
in an initial study in 2000 (5, 8, 9). In the large cohort studied
here, we found a slightly lower prevalence of 17%. Nonetheless,
patients with chronic cholestatic liver injury had reduced survival
in our study, underlining the need to identify potential risk factors
or predictors.
An elegant study in mice receiving parenteral nutrition
demonstrated that an intact gut barrier is pivotal to prevent
TABLE 3 Uni- and multivariable logistic regression analysis for the association with chronic cholestasis1
ptpt Univariable analysis Multivariable analysis
ptpt
Item
Unadjusted HR
(95% CI) P value
Adjusted HR
(95% CI) P value
ptpt
Age at start of IVS, y 1.02 (0.99, 1.05) 0.327 —
Age at day of blood collection, y 1.02 (0.99, 1.05) 0.284 —
Sex
Male Reference —
Female 4.39 (0.97, 19.78) 0.054 6.55 (1.33, 32.30) 0.021
BMI, kg/m2 1.02 (0.91, 1.14) 0.737 —
Terminal ileum resection
No Reference —
Yes 3.33 (1.20, 8.90) 0.021 —
Small bowel length (n = 119) 1.95 (1.29, 2.96) 0.002 —
≥ 200 cm (n = 70) Reference —
≥ 100 – <200 cm (n = 19) 3.81 (1.02, 14.26) 0.047 —
≥ 50 – <100 cm (n = 17) 5.82 (1.59, 21.35) 0.008 —
<50 cm (n = 13) 6.67 (1.65, 26.93) 0.008 —
Cholecystectomy
No Reference —
Yes 3.19 (1.26, 8.10) 0.015 —
Oral intake (n = 125)
No Reference —
Yes (n = 117) 0.65 (0.08, 5.59) 0.697 —
Fibroscan (n = 67) 1.06 (0.98, 1.13) 0.129 —
Duration of IVS,2 mo 1.00 (0.99, 1.01) 0.995 —
Type of IVS
i.v. fluids only Reference —
HPN 4.21 (0.53, 33.27) 0.173 —
IVS infusions (n = 116) 1.05 (0.80, 1.36) 0.739 —
Energy intake, kcal · kg−1 · d−1 1.01 (0.97, 1.05) 0.661 —
i.v. lipids ≥ 1 g · kg−1 · d−1 (n = 115)
No Reference —
Yes (n = 34) 0.47 (0.15, 1.50) 0.201 —
IVS volume, mL/d 1.00 (1.00, 1.00) 0.351 —
FGF19
High concentrations (> 107 pg/mL) Reference —
Low concentrations (≤ 107 pg/mL) 3.85 (1.08, 12.75) 0.038 3.76 (1.00, 14.10) 0.049
Citrulline
High concentrations (> 20 μmol/L) Reference —
Low concentrations (≤ 20 μmol/L) 5.36 (1.91, 15.00) 0.001 5.94 (1.89, 18.65) 0.002
C4, ng/mL 0.99 (0.99, 1.00) 0.260 —
Total bile salts, μmol/L 1.01 (0.98, 1.03) 0.661 —
CRP, mg/L (n = 120) 1.02 (0.99, 1.06) 0.108 —
pt 1Duration of IVS is the time difference between the start of IVS and day of blood collection. CRP, C-reactive protein; FGF, fibroblast growth factor; HPN, home parenteral
nutrition; i.v., intravenous; IVS, intravenous supplementation.
2HPN only or HPN + i.v. fluid, number of infusions per week.
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FIGURE 2 Kaplan–Meier curves for patients stratified for CIT (A) or FGF19 (B). Patients with CIT concentrations <20 μM had a significantly lower
survival than patients with higher concentrations of CIT (log-rank test, P < 0.0001). Patients with FGF19 concentrations <107 pg/mL tended to have a lower
survival than patients with high concentrations of FGF19 (log-rank test, P = 0.060). CIT, citrulline; FGF, fibroblast growth factor.
cholestatic liver injury, because intestinal inflammation promoted
bacterial translocation and LPS-induced Kupffer cell activation
and inflammatory sequelae (26). In addition, intestinal inflam-
mation was associated with low concentrations of FGF19 in
pediatric IF (13). Another study in pediatric patients with IF
due to surgical loss of the ileum showed that reduced FGF19
was associated with severity of fibrosis and liver inflammation
(19). Here we show, for the first time to our knowledge, that
low concentrations of FGF19 are associated with cholestatic liver
injury in adult patients with IF. Because the ileum is the primary
source of FGF19 in the circulation, terminal ileum resection
was also independently associated with cholestatic liver injury.
Interestingly, low CIT was strongly associated with chronic
cholestatic liver injury, adding to the notion that adequate gut
function is critical in preventing liver injury.
What could be the mechanism underlying the association of
low FGF19/CIT with chronic cholestasis? First, recall that low
FGF19 concentrations in pediatric IF were related with increased
serum and hepatic bile salts and de-repressed bile salt synthesis
(13). Analysis of liver biopsies from these pediatric patients
revealed downregulation of the master regulator (i.e., Farnesoid
X Receptor) of hepatic bile salt homeostasis, and an elevated
hepatic bile salt content (13). Hepatic FXR repression was linked
to intestinal inflammation and likely resulted in hepatic bile salt
toxicity (15, 27). Accumulation of bile salts in the hepatocyte
is known to trigger inflammation-linked pathways and results
in immune-mediated liver injury (28). In our study, bile salt
synthesis was upregulated, as reflected by marked elevation of
circulating C4, in patients with loss of the ileum, replicating
earlier findings in SB patients (29). However, this was not
accompanied by elevation of plasma bile salts. Neither C4 nor
TBS concentrations were associated with chronic cholestasis.
This suggests that in the studied patients, the normal transport
direction of bile salts (i.e., towards the canalicular pole) is
maintained. In line, total bilirubin—reflecting liver secretory
function—is elevated, but within the normal range, in patients
with chronic cholestasis. Hence, chronic cholestasis is unlikely
due to hepatotoxic concentrations of bile salts. Alternatively,
low FGF19 could contribute to liver injury independently of
effects on bile salt synthesis, as its hepatic receptor (FGFR4)
has anti-inflammatory actions (30). Hence, loss of enterocytic-
derived FGF19 signal could make the liver more susceptible to
inflammation (30).
This study revealed a heretofore-unknown association of CIT
with chronic cholestasis. CIT is a nonproteinaceous amino
acid and urea cycle intermediate. Net release in the circulation
occurs exclusively in the intestines. Previous studies showed
that CIT reflects the absorptive capacity of the (remnant) small
bowel, independently of the degree of intestinal inflammation
(20, 31). Apart from stimulation of muscle protein synthesis
(32), no liver-specific actions of CIT have been described in
humans. An experimental study in septic rats treated with
CIT demonstrated hepatoprotective effects in terms of reduced
transaminases and lower release of proinflammatory cytokines
(33). CIT concentrations were negatively associated with GGT
(n = 115, ρ = −0.47, P < 0.0001) and ALP (n = 131,
ρ = −0.45, P < 0.0001) in our cohort. Rather than loss of
presumed hepatoprotective action, this more likely reflects a
reduced functional capacity of the small intestine (reduced bowel
length or injured small intestine) in CIF patients, which results in
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TABLE 4 Uni- and multivariable Cox proportional hazard regression analysis1
Univariable analysis Multivariable analysis
Item
Unadjusted HR
(95% CI) P value
Adjusted HR
(95% CI) P value
Age at start of IVS, y 1.02 (1.00, 1.05) 0.127 —
Age at day of blood collection, y 1.02 (1.00, 1.05) 0.111 —
Sex
Male Reference —
Female 0.93 (0.41, 2.09) 0.854 —
BMI, kg/m2 0.95 (0.86, 1.06) 0.388 —
Fibroscan (n = 67) 0.96 (0.89, 1.14) 0.964 —
Duration of IVS,2 mo 1.00 (0.995, 1.005) 0.932 —
Small bowel resection 1.58 (0.75, 3.33) 0.277 —
Small bowel length 1.30 (0.88, 1.78) 0.210 —
≥ 200 cm Reference —
≥ 100 – <200 cm 0.57 (0.07, 4.17) 0.593 —
≥ 50 – <100 cm 2.98 (1.17, 7.54) 0.022 —
<50 cm 1.05 (0.24, 4.67) 0.952 —
Type of IVS
i.v. fluids only Reference —
HPN 0.77 (0.27, 2.24) 0.630 —
IVS infusions3 (n = 116) 1.32 (1.03, 1.70) 0.027 1.39 (1.08, 1.79) 0.011
Energy intake, kcal · kg−1 · d−1 (n = 118) 1.03 (1.00, 1.07) 0.057 —
i.v. lipids ≥ 1 g · kg−1 · d−1 (n = 115)
No Reference —
Yes 1.02 (0.44, 2.36) 0.960 —
PN volume, mL/d (n = 115) 1.00 (1.00, 1.00) 0.084 —
FGF19
High concentrations (> 107 pg/mL) Reference Reference
Low concentrations (≤ 107 pg/mL) 2.81 (0.97, 8.11) 0.056 3.35 (1.11, 10.11) 0.032
Citrulline
High concentrations (> 20 μmol/L) Reference Reference
Low concentrations (≤ 20 μmol/L) 3.64 (1.71, 7.74) 0.001 3.34 (1.48, 7.51) 0.004
C4, ng/mL 0.99 (0.996, 1.002) 0.533 —
Total bile salts, μmol/L 1.01 (0.99, 1.03) 0.532 —
CRP, mg/L (n = 120) 1.02 (1.00, 1.05) 0.065 —
1CRP, C-reactive protein; FGF, fibroblast growth factor; HPN, home parenteral nutrition; i.v., intravenous; IVS, intravenous supplementation; PN,
parenteral nutrition.
2Duration of IVS is the time difference between the start of IVS and day of blood collection.
3HPN only or HPN + i.v. fluid, number of infusions per week.
low CIT. Ultimately, by the nature of the short gut, patients are at
risk of development of IFALD.
In line with earlier findings (8), (remnant) small bowel length
and terminal ileum resection were associated with chronic
cholestasis in the current study. Unlike earlier reports (5, 34), we
(and others [7, 8]) did not observe a relation between high-dose
intravenous lipids and chronic cholestasis. Because intravenous
lipid mixtures have been improved in composition (in terms of
a lower content of proinflammatory mediators derived from n–6
PUFAs in soybean oil) and clinicians are aware of the harmful
effects of high doses, intravenous lipids may no longer pose
a risk factor for chronic cholestasis. The majority of patients
received a lipid emulsion with a reduced amount of soybean
oil (ClinOleic: 80% olive oil, 20% soybean oil) as part of their
parenteral nutrition (Supplemental Table 1).
In this study, we analyzed the largest cohort of adult CIF
patients so far, aiming to identify blood factors that predict
survival. The 5-y survival rate (59%) was slightly lower than
in other reports, where 5-y survival ranged from 62% to 75%
(35–39). Thus far, previous studies did not explore frequency of
IVS infusions per week as a predictor of survival. Interestingly,
the number of IVS infusions per week was significantly
associated with survival (P = 0.027) and remained significant in
multivariable analyses. Obviously, a higher number of infusions
may increase the risk of HPN-related complications. The number
of IVS infusions per week, low FGF19, and low CIT, which
were incorporated in a risk model, are simple measurements and
objective variables and therefore have clinical utility. TheMESIF
risk score has not been validated yet using an external cohort, and
further evaluation and confirmation in future multicenter studies
are warranted.
The major strength of our study in this rare patient population
was the availability of blood samples and clinical information,
allowing us to identify predictors of outcome. Importantly, lon-
gitudinal measurements over a long period of time established the
stability, and hence validity, of single time point measurements.
The study has several limitations. First, a validation cohort was
not available and the results thus need to be interpreted with
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FIGURE 3 Kaplan–Meier curves for patients with low, intermediate,
and high MESIF scores. Patients with high MESIF scores (> 40) had a
significantly lower 5-y survival rate than patients with low (scores between 0
and 20) or intermediate (scores between 20 and 40) MESIF scores (log-rank
test, P < 0.0001). MESIF, Model for End-Stage Intestinal Failure.
caution. Replication studies should be performed to scrutinize the
association of CIT and FGF19 with progressive liver disease and
to assess the general validity of the MESIF score. Second, some
patients received prescribed drugs, but the potential contribution
of these drugs to chronic cholestasis could not be taken into
account. Lastly, data from this study are limited by the low event
rates of chronic cholestasis (17%) and death (21%), which could
potentially lead to overestimation of the reported OR and HR.
Data from this study could be useful for clinicians taking care
of adult HPN patients. In particular, patients with a high MESIF
score should be monitored more closely or referred earlier for
consultation in an intestinal transplantation center. Considering
the long waiting time until ITx of∼275 d (median time, Universi-
tair Ziekenhuis Leuven [Belgium], personal communication), the
referral of patients in the intermediate-risk group to ITx centers
should be considered. The rehabilitative ITx has a 5-y survival
rate of 83%, so early referral should be considered in view of the
favorable survival rate. Our study included both SB and non-SB
patients (mainly intestinal dysmotility patients), therefore results
could be applied to a larger group of patients compared with
other studies analyzing only SB patients. It is conceivable that
variables in the MESIF risk score could be used as criteria for
pre-emptive ITx screening. Further studies exploring this option
should be considered, because in a simulation study ITx has
been shown to improve the survival of CIF patients and to be
more cost-effective in CIF patients with a poor expected survival
(40). Because of its rarity, there is a lack of data in the adult
CIF population, which makes evidence-based clinical evaluation
of CIF challenging. Recently, a European program has been
launched (ATLAS Program) to create more awareness of this
devastating orphan disease, and to improve the standard care of
CIF patients.
In conclusion, low concentrations of FGF19 and CIT predicted
chronic cholestasis and were associated with poor survival in our
cohort of adult CIF patients. The MESIF score was associated
with survival of these patients. Validation studies are warranted
to assess the general utility of the MESIF risk score in the clinical
management of CIF patients.
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